EICHORCondition: Multiple Myeloma · Neoplasm, Plasma Cell · Multiple Myeloma in Relapse · Sponsor: Chongqing Precision Biotech Co., Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
This description comes directly from the study's public registry record.
Zhi Yang, PhD · 86-13206140093 · yangzhi@precision-biotech.com
Always discuss trial participation with your own doctor first.
| 920th Hospital of Joint Logistics Support Force | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04776330